Tilray, Inc. is a Canada-based CBD company that describes itself on its website as a “global leader in cannabis research, cultivation, processing, and distribution.” The company aspires “to lead, legitimize and define the future of our industry by building the world’s most trusted cannabis company.”
The company recently announced in a press release that it is importing Good Manufacturing Practices Certified CBD into the United States for two clinical trials. The clinical trials will be conducted by the NYU School of Medicin and will specifically test the CBD for treatment of patients with alcohol use disorders, post-traumatic stress disorders, and alcohol use disorders.
The first of the clinical trials will be double-blind and randomized, designed to assess CBD treatment for those who have AUD. Those leading the trial will evaluate factors such as safety and tolerability of using CBD on a regular basis among the treatment population. It will